BioPharmX (BPMX) Promising Anti-acne Approach; Gabelli Visualizes Upside In Royal Gold (RGLD)


Shares of BioPharmX Corp. (NYSEMKT:BPMX) skyrocketed more than 135% to touch the $2.74 mark in early trading Friday after the company said that its topical gel antibacterial BPX-01 was safely absorbed and nontoxic in animals and in vitro human skin, representing a potential more effective anti-acne treatment than other topical options for the 40-50 million Americans suffering with the condition, according to BioPharmX’s research.

BPMX stock is currently exchanging hands for about $2.39, up $1.24 (or +107.83%), and 4,309,005 of its shares were traded so far, a huge increase in activity versus its average volume (3m) of 34,871

BioPharmX, a specialty pharmaceutical company, has 21.01M Shares Outstanding and BPMX 52-week range is between $0.91 and $4.50 per share



Investment analysts at Gabelli & Co. initiated coverage on Royal Gold, Inc. (Nasdaq:RGLD) shares with a Buy rating and a price target of $45.00

Royal Gold recently reported first quarter fiscal 2016 revenue of $74.1 million, a 7% increase year-over-year

Shares of RGLD are currently trading at $38.20, up $1.43 (or +3.89%) on Friday’s market activity

Royal Gold, which acquires and manages precious metals royalties, metal streams, and similar interests, has 65.29M Shares Outstanding and RGLD stock one-year range is from $34.42 to $77.20 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at